Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib-based chemo-light regimen for pediatric Ph+ ALL
NCT07152041Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of olverembatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2025; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT07152041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152041.